Why Shares of Cassava Sciences Rose 15% Today | The Motley Fool

0 5
What happened Shares of Cassava Sciences (NASDAQ:SAVA) -- the biotech company responsible for Alzheimer's drug candidate simufilam -- are up 15% as of Thursday's market close after the company released interim data from a study funded by the National Institutes of Health.  So what Its treatment focuses on restoring the shape of a scaffolding protein in the brain. The theory is that the misfolding of that protein leads to inflammation and degeneration of neurons in the brain. Image source: Getty Images. According to management, data from the first 50 patients to receive treatment, who had mild to moderate Alzheimer's, showed improved cognition scores after 12 months. It reported 68% of those patients saw improvement. The results come after a great deal of controversy last month over  images used in its data. The fireworks started after law firm Labaton Sucharow filed a citizen petition with the Food and Drug Administration. The firm
Subscribe or log in to read the rest of this content.
Leave A Reply

Your email address will not be published.

At The Centre of Every Trade